Skip to main content

Equibles does not estimate personal net worth.

Get an email with a short summary when Damora Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.

Get DMRA alerts

About Lori Firmani

Lori Firmani is recorded as CFO at Damora Therapeutics, Inc. (DMRA). The newest filing on record that lists Lori Firmani as CFO at Damora Therapeutics, Inc. (DMRA) is dated April 29, 2026. Damora Therapeutics, Inc. reported in an 8-K filed November 10, 2025 that Lori Firmani was appointed Chief Financial Officer, effective November 10, 2025. The proxy statement of Damora Therapeutics, Inc. reports total compensation of $563,211 for Lori Firmani in fiscal 2025, including a base salary of $311,249. Disclosed compensation is on record for 2 fiscal years. Damora Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Damora Therapeutics, Inc. includes Jennifer Jarrett (CEO and Board Member), Sherwin Sattarzadeh (CEO and COO), Peter Harwin (Chairman and Board Member) and 7 others.

“The Board appointed Ms. Firmani as Chief Financial Officer of the Company and approved an increase in Ms. Firmani's base salary from $300,000 to $375,000.”
Damora Therapeutics, Inc. Form 8-K, filed November 10, 2025 · Read the filing

Affiliation history

Company network

Leadership on record at Damora Therapeutics, Inc.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2025 Damora Therapeutics, Inc. (DMRA) $311,249 $563,211
2024 Damora Therapeutics, Inc. (DMRA) $261,188 $561,892

Recent activity